

Oncology Today with Dr Neil Love: Biomarker-Directed Therapy for Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug combinations was recently FDA approved on the basis of results of the Phase III BEACON CRC trial for patients with previously treated metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation?
 - a. Encorafenib/cetuximab
 - b. Encorafenib/binimetinib/FOLFIRI
 - c. Encorafenib/cetuximab/binimetinib
2. What is the approximate frequency of HER2 amplification in patients with KRAS wild-type mCRC?
 - a. 1% to 2%
 - b. 5% to 6%
 - c. 9% to 10%
3. Which of the following outcomes was NOT reported in the MOUNTAINEER trial evaluating trastuzumab with tucatinib for HER2-amplified mCRC?
 - a. Elevated aspartate aminotransferase
 - b. No Grade 4 or 5 treatment-related adverse events
 - c. Median duration of response not reached
 - d. Overall response rate of approximately 25%
4. Which of the following progression-free survival (PFS) outcomes has been reported from the Phase III KEYNOTE-177 trial comparing pembrolizumab to standard chemotherapy for the first-line treatment of microsatellite instability-high or mismatch repair-deficient mCRC?
 - a. Significant improvement in PFS2 but not PFS with pembrolizumab
 - b. Significant improvement in PFS but not PFS2 with pembrolizumab
 - c. Significant improvement in both PFS and PFS2 with pembrolizumab
 - d. No significant difference in either PFS or PFS2 between the study arms